Vaccines

10 May 2021

INOVIO Announces Positive Data from Phase 2 Segment of Clinical Trial Evaluating INO-4800, its COVID-19 DNA Vaccine

8 May 2021

Vaxart Announces First Subject Enrolled in Phase 1b Norovirus Dose-Ranging Trial in Elderly Adults

7 May 2021

Pfizer and BioNTech Initiate Rolling Submission of Biologics License Application for U.S. FDA Approval of Their COVID-19 Vaccine

6 May 2021

Moderna Announces Positive Initial Booster Data Against SARS-CoV-2 Variants of Concern

4 May 2021

New Data from Vaxart Oral COVID-19 Vaccine Phase I Study Suggests Broad Cross-Reactivity against Other Coronaviruses

4 May 2021

Enesi Pharma Achieves Preclinical Proof-of-Concept with ImplaVax®-Enabled Pandemic Influenza Vaccine

30 April 2021

Pfizer and BioNTech Submit Request to Expand Conditional Marketing Authorization of COMIRNATY® in the EU to Adolescents

24 April 2021

INOVIO Planning for ex-US Global Phase 3 Trial for INO-4800

24 April 2021

Johnson & Johnson Single-Shot COVID-19 Vaccinations to Resume in the U.S. for All Adults Aged 18 and Older Following CDC and FDA Decision

22 April 2021

Valneva Initiates Pivotal Phase 3 Clinical Trial for its Inactivated, COVID-19 Vaccine Candidate using Dynavax’s CpG 1018™ Adjuvant

22 April 2021

Sirnaomics’ Spin-Off RNAimmune Secures $10 Million Seed Financing to Advance its mRNA-Based Vaccine and Therapeutic Development

18 April 2021

Aegis Life Announces Start of Phase 1/2 Trial of the Entos COVID-19 DNA Vaccine, Covigenix VAX-001, with First Participants Dosed

15 April 2021

INOVIO’s COVID-19 Vaccine Candidate, INO-4800, Provides Broad Cross-reactive Immune Responses In Humans Against Variants of Concern

13 April 2021

Intravacc announces positive preclinical data for its OMV-based Lyme vaccine

13 April 2021

Applied DNA and Evvivax Announce Positive Preliminary Results of Phase I Clinical Trial for LinearDNA™ COVID-19 Vaccine Candidate in Felines

12 April 2021

Akston Biosciences Launches Phase I/II Clinical Trial of Second-Generation COVID-19 Vaccine

12 April 2021

VBI Vaccines Announces Phase 1b/2a Data and Progress of Hepatitis B Immunotherapeutic Candidate

11 April 2021

HOOKIPA announces positive preliminary Phase 1 immunogenicity data for its immunotherapy candidates to treat advanced HPV16+ cancers

11 April 2021

Greenwich LifeSciences Presents Immune Response Phase IIb Poster, Published Today at AACR 2021, Showing Peak Immunity after 6 Months of GP2 Treatment, Resulting in 100% Disease Free Survival from Recurring Breast Cancer

7 April 2021

ERC-USA Announces FDA Recommendation for Early Termination of Phase 2 Clinical Trial of ERC1671 (Gliovac or Sitoiganap) and Application for Registration Trial for Treatment of Glioblastoma

7 April 2021

Icosavax Closes $100 Million Series B Financing to Advance Bivalent RSV/hMPV Vaccine Candidate Into Clinical Trials

7 April 2021

Intravacc announces positive preclinical data for its SARS-CoV-2 nose spray vaccine

6 April 2021

Valneva Reports Positive Phase 1/2 Data for Its Inactivated, Adjuvanted COVID-19 Vaccine Candidate, VLA2001

6 April 2021

Novavax Initiates COVID-19 Vaccine Clinical Trial Crossover

2 April 2021

OSE Immunotherapeutics Receives Authorization for Phase 1 Clinical Trial of its Multi-Target Multi-Variant COVID-19 Vaccine

2 April 2021

Pfizer and BioNTech Confirm High Efficacy and No Serious Safety Concerns Through Up to Six Months Following Second Dose in Updated Topline Analysis of Landmark COVID-19 Vaccine Study

31 March 2021

Pfizer-BioNTech Announce Positive Topline Results of Pivotal COVID-19 Vaccine Study in Adolescents

30 March 2021

Curevo Vaccine Announces the Approval to Conduct a Phase 1b Clinical Trial in South Africa to Evaluate Safety and Immunogenicity of Its Adjuvanted Subunit Investigational Vaccine, CRV-101, Against Varicella (Chickenpox) in HIV-Positive Children

29 March 2021

Gritstone Announces First Person Dosed with its Second-Generation COVID-19 Vaccine in Phase 1 Study Conducted and Supported by NIAID/IDCRC

27 March 2021

Phase 2b VITAL study of Gemogenovatucel-T (Vigil™) immunotherapy demonstrates clinical benefit in homologous recombination (HR) proficient ovarian cancer

News Channels

Newsletter

La Merie Biologics

La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.

Newsletter La Merie Biologics

Newsletter

New Product Alert

La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.

Newsletter new product alert

Featured reports

Claudin 6, Cadherin 17, ROR1 and GPRC5D-Targeted Therapies: Target Expression Profile, Safety & Efficacy of Drug Modalities, Pipeline Review, and Competitive Landscape Analysis

2020 Sales of Recombinant Therapeutic Antibodies, Proteins, Biosimilars & Other Biologics

5T4-Targeted Immunotherapy Candidates Pipeline Review

Ranibizumab (Lucentis) Biosimilars Pipeline Review

CCR8-Targeted Antibody Immunotherapy Pipeline Review

ROR1-Targeted Therapy: Target Expression Profile, Safety & Efficacy of Drug Modalities, Pipeline Review, and Competitive Landscape Analysis

Ustekinumab (Stelara) Biosimilars Pipeline Review

TL1A Inhibitor Pipeline Review

Blockbuster Biologics 2017: Sales of Recombinant Therapeutic Antibodies & Proteins

B7-H4 Targeted Antibody Therapy Pipeline Review